Study S000176

A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice

ClinicalTrials.gov record

Registration

Registration: NCT06857942
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 200
Start: 2025-03-19
Primary completion: 2028-05
Lead sponsor: Eli Lilly and Company
Conditions: Psoriasis; Overweight or Obesity
Interventions: DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I1F-MC-RHDD

Registered primary outcomes

Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) (0,1) [12 months]
Percentage of Participants Achieving at least 10% Weight Reduction [12 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.